Cargando…

Who’s Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma

SIMPLE SUMMARY: Here, we monitored the course of the disease and treatment of sinonasal melanoma patients. Since treatment options are rare, immunotherapy is often the treatment of choice. However, intrinsic or acquired resistance to treatment may occur. We assessed the mutational status of the tumo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freiberger, Sandra N., Turko, Patrick, Hüllner, Martin, Dummer, Reinhard, Morand, Grégoire B., Levesque, Mitchell P., Holzmann, David, Rupp, Niels J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198298/ https://www.ncbi.nlm.nih.gov/pubmed/34072863 http://dx.doi.org/10.3390/cancers13112725

Ejemplares similares

Morpho-Molecular Assessment Indicates New Prognostic Aspects and Personalized Therapeutic Options in Sinonasal Melanoma
por: Freiberger, Sandra N., et al.
Publicado: (2019)

Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients
por: Freiberger, Sandra N., et al.
Publicado: (2022)

Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma
por: Fröhlich, Fabienne, et al.
Publicado: (2023)

Tumor-stroma relationships: Who’s the driver?
por: Wooster, Richard F.
Publicado: (2012)

Longevity or hypoxia: who’s driving?
por: Pamenter, Matthew E., et al.
Publicado: (2019)

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance
por: Raaijmakers, Marieke I. G., et al.
Publicado: (2016)

Sinonasal mucosal melanoma treatment response assessment to immune checkpoint inhibitors using hybrid positron emission tomography imaging
por: Maurer, Alexander, et al.
Publicado: (2023)

The Prognostic Value of a Single, Randomly Timed Circulating Tumor DNA Measurement in Patients with Metastatic Melanoma
por: Boerlin, Aurelio, et al.
Publicado: (2022)

Loss of YY1, a Regulator of Metabolism in Melanoma, Drives Melanoma Cell Invasiveness and Metastasis Formation
por: Guendisch, Ulf, et al.
Publicado: (2022)

Reappraisal of Grading in Intestinal-Type Sinonasal Adenocarcinoma: Tumor Budding as an Independent Prognostic Parameter
por: Meerwein, Christian M., et al.
Publicado: (2022)

Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma
por: Tusup, Marina, et al.
Publicado: (2021)

Correction: Stalder, et al.; Value of SUV(max) for the Prediction of Bone Invasion in Oral Squamous Cell Carcinoma. Biology 2020, 9, 23
por: Stalder, Stephanie A., et al.
Publicado: (2020)

Value of SUV(max) for the Prediction of Bone Invasion in Oral Squamous Cell Carcinoma
por: Stalder, Stephanie A., et al.
Publicado: (2020)

The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma
por: Restivo, Gaetana, et al.
Publicado: (2017)

Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suv(max)) In Laryngeal and Hypopharyngeal Cancer
por: Werner, Jonas, et al.
Publicado: (2019)

Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
por: Dummer, Reinhard, et al.
Publicado: (2017)

Publisher Correction: The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma
por: Restivo, Gaetana, et al.
Publicado: (2018)

Who’s in and Who’s Out? Selection Bias in Aging Research
por: Mayeda, Elizabeth Rose, et al.
Publicado: (2020)

Disparities in access to fertility care: who’s in and who’s out
por: Galic, Isabel, et al.
Publicado: (2020)

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy
por: DIMITRIOU, Florentia, et al.
Publicado: (2020)

Who’s Who
Publicado: (2022)

Who’s Driving? Human Cytomegalovirus, Interferon, and NFκB Signaling
por: Goodwin, Christopher M., et al.
Publicado: (2018)

Evolution in Sinonasal Mucosal Melanoma Management
por: Richa, Tony, et al.
Publicado: (2022)

Look Who’s Talking: Host and Pathogen Drivers of Staphylococcus epidermidis Virulence in Neonatal Sepsis
por: Joubert, Isabella A., et al.
Publicado: (2022)

ROR2, a driver of “phenotype switching” in melanoma?
por: Lopez-Bergami, Pablo
Publicado: (2022)

Biomarkers for Immunotherapy in Poorly Differentiated Sinonasal Tumors
por: Villanueva-Fernández, Eva, et al.
Publicado: (2022)

Who’s got TALENT?
por: Joannah Caborn Wengler
Publicado: (2012)

Melanoma patients with additional primary cancers: a single-center retrospective analysis
por: Dimitriou, Florentia, et al.
Publicado: (2019)

PTEN Methylation Dependent Sinonasal Mucosal Melanoma
por: Lee, Sang Hee, et al.
Publicado: (2016)

Contemporary Multidisciplinary Management of Sinonasal Mucosal Melanoma
por: Na’ara, Shorook, et al.
Publicado: (2020)

Methylation Drivers and Prognostic Implications in Sinonasal Poorly Differentiated Carcinomas
por: Libera, Laura, et al.
Publicado: (2021)

Predictive value of suvmax changes between two sequential post-therapeutic FDG-pet in head and neck squamous cell carcinomas
por: Stadler, Thomas M., et al.
Publicado: (2020)

Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2022)

Expanding the clinicopathological spectrum of TGFBR3‐PLAG1 rearranged salivary gland neoplasms with myoepithelial differentiation including evidence of high‐grade transformation
por: Rupp, Niels J., et al.
Publicado: (2021)

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy
por: Smith, Michael P., et al.
Publicado: (2016)

Correction: Tusup et al. Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma. Non-Coding RNA 2021, 7, 5
por: Tusup, Marina, et al.
Publicado: (2022)

Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2023)

Histopathological Analysis of Nodal Disease After Chemoradiation Reveals Viable Tumor Cells as the most Important Prognostic Factor in Head and Neck Squamous Cell Carcinoma, DOI 10.1007/s12105-023-01557-7
por: Morand, Grégoire B., et al.
Publicado: (2023)

Genetic heterogeneity and transcriptional plasticity drive resistance during immunotherapy and targeted therapy
por: Dummer, Reinard
Publicado: (2015)

Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden
por: Ak, Melike, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hrdd959ut2ndls4hr3jh7kd7t0